Does Retatrutide Have Evidence Regarding Atherosclerosis?
No, retatrutide does not currently have direct evidence demonstrating benefit on atherosclerosis or atherosclerotic cardiovascular disease (ASCVD) outcomes in adults with obesity without diabetes. While retatrutide shows promising effects on cardiovascular risk factors, no completed cardiovascular outcomes trials exist for this medication.
Current Evidence Status
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors that has demonstrated substantial weight loss (up to 24-26% at 48 weeks) in clinical trials 1, 2, 3. However, the evidence base consists entirely of Phase 1-3 trials focused on weight loss and metabolic parameters—not on hard cardiovascular endpoints like myocardial infarction, stroke, or cardiovascular death 4, 1.
Cardiovascular Risk Factor Improvements
While not direct atherosclerosis evidence, retatrutide does improve several ASCVD risk factors:
Blood Pressure Reduction
- Systolic BP decreases by 6.79 mmHg (95% CI: -8.36 to -5.23 mmHg)
- Diastolic BP decreases by 2.46 mmHg (95% CI: -3.25 to -1.67 mmHg) 5
These reductions are comparable to those seen with tirzepatide (8.0 mmHg systolic reduction) 6, where 70% of BP benefit was mediated by weight loss.
Lipid Profile Improvements
Retatrutide significantly reduces:
- Total cholesterol by 21.88 mg/dL (95% CI: -27.79 to -15.97 mg/dL)
- LDL-C by 13.10 mg/dL (95% CI: -16.10 to -10.10 mg/dL)
- Triglycerides by 40.90 mg/dL (95% CI: -48.50 to -33.30 mg/dL)
- No significant effect on HDL-C 5
Metabolic Improvements
- HbA1c reduction up to 2.16% in patients with type 2 diabetes 7
- Insulin resistance improvement (reduced HOMA-IR) 8
- Hepatic steatosis reduction (86% reduction in liver fat in MASLD patients) 7
Critical Gap: No Cardiovascular Outcomes Data
The fundamental limitation is the absence of cardiovascular outcomes trials. This contrasts sharply with other incretin-based therapies:
- Semaglutide: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and established CVD (HR 0.80,95% CI: 0.72-0.90) 9
- Liraglutide: The LEADER trial showed reduced MACE in patients with type 2 diabetes (HR 0.87,95% CI: 0.78-0.97) 10, 11
- Tirzepatide: Currently under investigation in cardiovascular outcomes trials
For retatrutide, no such data exists yet. The improvements in risk factors are encouraging but do not constitute evidence of atherosclerosis benefit 10.
Clinical Context from Guidelines
The 2013 ACC/AHA cholesterol guidelines emphasize that cardiovascular outcomes, not just risk factor modification, should guide treatment decisions 12. The 2020 Endocrine Society guideline notes that for weight loss medications, "there is no evidence that medications at the doses approved for weight reduction reduce CV mortality or morbidity in individuals with obesity" without diabetes 10.
The 2024 ILEP recommendations on atherosclerosis management focus on proven lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) with established cardiovascular outcomes data 13. Weight loss medications are not mentioned as primary atherosclerosis treatments.
Important Caveats
Phase 3 trials are ongoing for type 2 diabetes, obesity, and NAFLD (started August 2023) 3, but cardiovascular outcomes data will take years to mature
Preclinical data shows metabolic benefits in mouse and hamster MASH models, including reduced hepatic triglycerides and improved insulin resistance 8, but this does not translate to proven atherosclerosis benefit in humans
Safety profile is similar to GLP-1 agonists, with predominantly mild-to-moderate gastrointestinal adverse events 2, 14
Lean mass loss comprises approximately 25-39% of total weight loss with incretin-based therapies 15, which may have implications for long-term cardiovascular health
Bottom Line
Retatrutide improves multiple cardiovascular risk factors but lacks direct evidence for atherosclerosis prevention or treatment. For adults with obesity without diabetes seeking to reduce atherosclerotic risk, proven interventions include intensive lifestyle modification, statins for appropriate LDL-C targets (<70 mg/dL for high-risk patients), and potentially semaglutide if established CVD is present 12, 13, 16. Retatrutide may be considered for weight loss and metabolic improvement, but cannot be recommended specifically for atherosclerosis management until cardiovascular outcomes trials are completed.